This Phase 2a trial tests whether adding an oral drug called ECC4703 to the weekly injection semaglutide helps adults with obesity lose more weight and reduce liver fat. About 151 participants will take either ECC4703 or a placebo alongside semaglutide for 20 weeks. The study is …
Phase: PHASE2 • Sponsor: Eccogene • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC